

NOXXON PHARMA AG TO PRESENT AT RODMAN & RENSHAW 8TH ANNUAL HEALTHCARE CONFERENCE, NEW YORK, NY, USA

Berlin, Germany, November 03, 2006 -- NOXXON Pharma AG (NOXXON), the next generation aptamer company and leader in Spiegelmer therapeutics, will present at Rodman & Renshaw 8th Annual Healthcare Conference in New York, NY, USA. The presentation is scheduled for November 6th at 12:45 pm in the Adams Room of the New York Palace Hotel.

Dr. Sven Klussmann, Chief Executive and Chief Scientific Officer of NOXXON, will provide a corporate overview of NOXXON, including the current status of development of the company's next generation aptamers. NOXXON is currently assembling investors for a series C round of financing to support the pre-clinical and clinical development of NOXXON's lead compounds NOX-A12 for the treatment of diabetic retinopathy and NOX-E36 for the treatment of renal inflammation.

About the event:

The Conference will include presentations by over 300 emerging growth biotechnology companies, as well as experts from the medical, scientific and investment communities. This premier event will unite companies with institutional investors, venture capitalists, senior corporate executives and experts from the scientific and medical communities. For more information or a schedule of presentations visit:

<http://www.rodmanandrenshaw.com/us06conference>.

About NOXXON Pharma AG, the next generation aptamer company:

Based on one of the largest and best protected patent portfolio, Berlin-based NOXXON Pharma AG develops biostable aptamers, novel substances based on mirror image nucleic acids. These so-called Spiegelmers® (the German word "Spiegel" means mirror) bind highly specific to the pharmacologically relevant target for which they were selected. Thanks to their structural characteristics, Spiegelmers® are extremely resistant to degradation and not immunogenic - a new generation of improved therapeutics.

Website info: <http://www.noxxon.net>

General contact: Esther Hildebrandt
NOXXON Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin, Germany
Phone: + 49 30 72 62 47 0
FAX: + 49 30 72 62 47 225
Email: ehildebrandt@noxxon.net